NEU neuren pharmaceuticals limited

Acadia, page-1357

  1. 34,586 Posts.
    lightbulb Created with Sketch. 9549
    I compiled a summary of US sales for DAYBUE and SKYCLARYS, same launch time, DAYBUE has been performing better than SKYCLARYS in sales in US.
    Given SKYCLARYS/Reata was acquired in 2023 for US$7.3B, NEU is still valued at US$1.05B with net cash around $320m including US$50m milestone payment to receive this quarter less accrued income tax.

    According to Acadia sale guidance, NEU will receive royalties for 2025 DAYBUE sales, royalties will be around $64m to $69m, then likely another milestone payment for first Europe sale of US$35m/$55m, and bank interest income around $16m, NEU 2025 income are likely to be around $135m to $140m, on top of existing net cash position of around $320m, based on my estimates.

    DYOR & ALL IMO.
    Screenshot 2025-02-27 065838.png
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$17.89
Change
0.010(0.06%)
Mkt cap ! $2.252B
Open High Low Value Volume
$17.93 $17.97 $17.64 $2.423M 135.9K

Buyers (Bids)

No. Vol. Price($)
9 321 $17.88
 

Sellers (Offers)

Price($) Vol. No.
$17.90 889 5
View Market Depth
Last trade - 10.39am 13/08/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.